Wilson Sonsini Goodrich & Rosati advised vTv Therapeutics on patent matters related to the transaction. vTv Therapeutics, a clinical-stage biopharmaceutical company, announced the closing of a private...
vTv Therapeutics’ $51 Million Private Placement Financing
Janux Therapeutics’ $296.5 Million Common Stock Offering
Cooley advised Janux Therapeutics on the offering and Wilson Sonsini Goodrich & Rosati advised Janux on patent matters. Latham & Watkins advised the underwriters. Janux Therapeutics,...
Avidity Biosciences’ $400 Million Shares Private Placement
Wilson Sonsini Goodrich & Rosati advised Avidity on patent matters related to the transaction. Avidity Biosciences, Inc. (Nasdaq: RNA) announced that it has agreed to sell 15,224,773...
Gilead’s Acquisition of XinThera
Wilson Sonsini Goodrich & Rosati advised XinThera on the transaction. Gilead Sciences announced the acquisition of San Diego-based XinThera, a privately held biotech company. The acquisition...
Tenaya Therapeutics’ $75 Million Shares Offering
Wilson Sonsini Goodrich & Rosati advised Tenaya on the deal, while Davis Polk advised the joint book-running managers and representatives of the several underwriters. Clinical stage...
CalciMedica’s $35 Million Merger with Graybug
Wilson Sonsini advised CalciMedica on the deal. Graybug Vision, Inc. and CalciMedica Inc. announced that they have entered into a definitive merger agreement to combine the...
MBX Biosciences’ $115 Million Series B Financing
Wilson Sonsini Goodrich & Rosati advised MBX Biosciences on the deal while WilmerHale advised Wellington Management. MBX Biosciences, Inc., a clinical stage biopharmaceutical company developing Precision...
ReCode Therapeutics’ $120 Million Series B Financing
Wilson Sonsini Goodrich & Rosati represented ReCode Therapeutics in the transaction. ReCode Therapeutics, a genetic medicines company using superior delivery to power the next wave of...
Scipher Medicine’s $110 Million Financing Round
Wilson Sonsini advised Scipher Medicine on the deal. Scipher Medicine, a precision immunology company matching each patient with their most effective therapy, announced the completion of...
Adanate’s $30 Million Series A Financing
Wilson Sonsini Goodrich & Rosati advised Adanate on the deal. Adanate, a biotech company focusing on therapies in oncology and immunology, recently raised $30 million in...
Hexagon Bio’s $61 Million Funding Round
Wilson Sonsini Goodrich & Rosati advised Hexagon Bio on the deal. Hexagon Bio, a biopharmaceutical company pioneering the discovery of medicines encoded in the global metagenome,...
Bayer AG’s Acquisition of Vividion Therapeutics
Cooley and Wilson Sonsini Goodrich & Rosati advised Vividion Therapeutics on the deal. Vividion Therapeutics, a biopharmaceutical company utilizing novel discovery technologies to unlock high-value, traditionally...